ProBioGen has entered an agreement with Polpharma Biologics.
Under the agreement, ProBioGen will conduct cell line development services for Polpharma's biosimilar, supporting the expansion of its current biologics pipeline.
By leveraging its cell line development platform CHO.RiGHT, ProBioGen will create a robust production cell line with a high yield.
This will allow Polpharma to meet the growing interest in its biosimilars, while ensuring the high quality therapeutic is produced quickly and safely.
The development of biosimilars requires rigorous testing and fine-tuning to ensure they are as safe and effective as the original biologics — which ProBioGen will contribute to.
Through this and future collaborations, both companies aim to accelerate development timeline and drive the production of next-gen therapies.
"We are excited to support Polpharma Biologics in bringing their product to the clinic," said Dr. Volker Sandig, Chief Scientific Officer at ProBioGen.
"By applying our extensive expertise in cell line engineering, we provide Polpharma with best-in-class expression platform that ensures efficiency, expression stability and superior quality."
Dr. Konstantin Matentzoglu, Supervisory Board Member from Polpharma Biologics, added: "Partnering with a reliable CDMO to support our expanding capacity needs was crucial."
u"ProBioGen's track record, proven expertise, agility and dedication to high-standard services were key factors in our decision to collaborate. This partnership reflects the increasing demand for biosimilars and reinforces our commitment to improving patient access while reducing healthcare costs by using high-expressing production cell lines."